Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects

Johannsen, Trine Holm, Frikke-Schmidt, Ruth, Schou, Jesper, Nordestgaard, Børge G., Tybjærg-Hansen, Anne·2012·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2012.07.045

Cited by (156)

Items 101–156 of 156

  1. Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma
    Ken Yamada, Margaret E. Brousseau, Wataru Honma, Akiko Iimura, Hidetomo Imase, Yuki Iwaki, Toshio Kawanami, Daniel LaSala, Guiqing Liang, Hironobu Mitani et al. · 2017 · Journal of Medicinal Chemistry
  2. Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options
    Ference, Brian A. · 2019 · Clinical Pharmacology & Therapeutics
  3. The association of childhood HDL cholesterol with atherosclerotic cardiovascular disease events in adults: findings from the International Childhood Cardiovascular Cohort Consortium
    Jing Wang, Noora Kartiosuo, Olli Tuomas Raitakari, Jorma S.A. Viikari, Markus Juonala, Lydia Bazzano, Alan R. Sinaiko, Julia Steinberger, Stephen R. Daniels, Alison Venn et al. · 2025 · European Journal of Preventive Cardiology
  4. Genetics for the Identification of Lipid Targets Beyond PCSK9
    Linda R. Wang, Robert Alexander Hegele · 2016 · Canadian Journal of Cardiology
  5. Genetic Lipid Disorders Associated with Atherosclerotic Cardiovascular Disease
    Reed Mszar, Gayley Webb, Vivek Kulkarni, Zahid Ahmad, Daniel E. Soffer · 2022 · Medical Clinics of North America
  6. Einfluss der Lipidstoffwechselparameter auf die Entstehung und Progression der koronaren Herzerkrankung
    David Sinning, David M. Leistner, Ulf Landmesser · 2016 · Herz
  7. Anacetrapib as a potential cardioprotective strategy
    Belinda A. Di Bartolo, Stephen James Nicholls · 2017 · Drug Design Development and Therapy
  8. Plakophilin-2 c.419C>T and risk of heart failure and arrhythmias in the general population
    Alex Hørby Christensen, Pia R. Kamstrup, Estelle Gandjbakhch, Marianne Benn, Jan Skov Jensen, Henning Bundgaard, Eric Villard, Anne Tybjærg‐Hansen · 2015 · European Journal of Human Genetics
  9. Genome-wide association analysis of HDL-C in a Lebanese cohort
    Rebecca A. Deek, Jason Nasser, Anthony Ghanem, Marc Mardelli, Georges Khazen, Angelique K. Salloum, Antoine Abchee, Michella Ghassibe‐Sabbagh, Pierre Zalloua · 2019 · PLoS ONE
  10. Lower LDL is better – can this be achieved with CETP inhibition therapy?
    Shirya Rashid · 2020 · Expert Review of Cardiovascular Therapy
  11. Cholesteryl Ester Transfer Protein Deficiency and Hyperalphalipoproteinemia
    Akihiro Inazu · 2025 · Journal of Atherosclerosis and Thrombosis
  12. Obicetrapib for dyslipidemia with or without cardiovascular risk: A GRADE ‐assessed meta‐analysis of randomized trials with trial sequential evidence
    Ahmed Emara, Ahmed Farid Gadelmawla, Ameer Awashra, Mohamed K Rifai, Mohamed S. Elgendy, Ahmed Diaa, Mohamed R. Emara, Ramez M. Odat, Abdalrahman Assaassa, Abdalhakim R. M. Shubietah · 2025 · Diabetes Obesity and Metabolism
  13. Genetic support of causal association between lipid and glucose metabolism and stress urinary incontinence in women: a bidirectional Mendelian randomization and multivariable-adjusted study
    Nanyan Xiang, Shiqi Su, Yong Yang, Yurui Luo, Tingting Fu, Le Wang, Yifei Lin, Jin Huang · 2024 · Frontiers in Endocrinology
  14. Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?
    Stephen James Nicholls, Sean Tan, Julie Butters, Adam J. Nelson · 2024 · Expert Opinion on Pharmacotherapy
  15. Anacetrapib in familial hypercholesterolaemia: pros and cons
    Frederick Johan Raal, Dirk Jacobus Blom · 2015 · The Lancet
  16. Single Nucleotide Polymorphisms in Cholesteryl Ester Transfer Protein Gene and Recurrent Coronary Heart Disease or Mortality in Patients With Established Atherosclerosis
    Salim S. Virani, Vei‐Vei Lee, Ariel Brautbar, Megan L. Grove, Vijay Nambi, Mahboob Alam, MacArthur A. Elayda, James M. Wilson, James T. Willerson, Eric Boerwinkle et al. · 2013 · The American Journal of Cardiology
  17. The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?
    Eder C.R. Quintão · 2016 · European Journal of Clinical Investigation
  18. Impact of variants in CETP and apo AI genes on serum HDL cholesterol levels in men and women from the Polish population
    Marta Włodarczyk, Małgorzata Wrzosek, Grażyna Nowicka, Beata Jabłonowska-Lietz · 2016 · Archives of Medical Science
  19. The evolution of lipid-lowering drugs in the management of cardiovascular disease risk: From the first cardiovascular disease risk–reducing therapies to the novel challenging strategies
    Doriane Henry, Eric Baugé, Bart Staels, Fanny Lalloyer · 2025 · Pharmacological Reviews
  20. Lipids and cardiovascular disease 3 Triglycerides and cardiovascular disease
    Børge Grønne Nordestgaard, Anette Varbo · 2014
  21. Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An Update
    Igor Domański, Aleksandra Kozieł, Jurand Domański, Małgorzata Trocha · 2026 · Journal of Clinical Medicine
  22. High-Density Lipoprotein Cholesterol and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Statins: An Observation from the REAL-CAD Study
    Kazunori Omote, Isao Yokota, Toshiyuki Nagai, Ichiro Sakuma, Yoshihisa Nakagawa, Kiwamu Kamiya, Hiroshi Iwata, Katsumi Miyauchi, Yukio Ozaki, Kiyoshi Hibi et al. · 2021 · Journal of Atherosclerosis and Thrombosis
  23. Application of Genetic Epidemiology to CETP (Cholesteryl Ester Transfer Protein) Concentration and Risk of Cardiovascular Disease
    Tony Raymond Merriman · 2018 · Circulation Genomic and Precision Medicine
  24. Associations Between Gene Variants of Lipid‐Lowering Drug Targets and Adverse Outcomes After Ischemic Stroke
    Lulu Sun, Qilu Zhang, Mengyao Shi, Yang Liu, Zhengbao Zhu, Jing Zhang, Hao Yang Peng, Aili Wang, Jing Chen, Tan Xu et al. · 2024 · Journal of the American Heart Association
  25. Genetic insights of lipid metabolism and lipid-lowering drugs with Lewy body dementia risk: Evidence from Mendelian randomization
    Hanyu Zhang, Zengyuan Zhou, Jie Gu, Yingnan Lin, Yunyun Yan, Xiaonan Chen, Meixiang Fan, Yanyan Huang · 2025 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  26. Anacetrapib
    Lacey B. Robinson, William H. Frishman · 2014 · Cardiology in Review
  27. CETP Deficiency and Concerns in CETP Inhibitor Development
    Akihiro Inazu · 2017 · Elsevier eBooks
  28. Cholesteryl Ester Transfer Protein Inhibitors
    Akihiro Inazu · 2013 · Elsevier eBooks
  29. Association of the CETP gene TaqIB and D442G polymorphisms with essential hypertension in the Chinese Mongolian population
    Shudong NIU, Xiao-ming Tao, Jingping Li, Yongyue Liu, Jian WANG, Mingyu Cong, Keyong Zhang, Wenyu Zhou, Changchun Qiu · 2017 · TURKISH JOURNAL OF MEDICAL SCIENCES
  30. Discovery of High-Density Lipoprotein Gene Targets from Classical Genetics to Genome-Wide Association Studies
    Lita A. Freeman, Alan Thomas Remaley · 2015 · Elsevier eBooks
  31. News on the genetics of lipoprotein metabolism and cardiovascular disease
    Bart van de Sluis, Jan Albert Kuivenhoven · 2013 · Current Opinion in Lipidology
  32. Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trials
    Liffert Vogt, Michael H Davidson, Michael J. Szarek, Douglas Kling, Mary R. Dicklin, Danielle Curcio, Marc Ditmarsch, Andrew Hsieh, Douglas L. Wicks, Nancy Ortiz et al. · 2026 · American Journal of Preventive Cardiology
  33. What does the future hold for cholesteryl ester transfer protein inhibition?
    Benoît J. Arsenault, Marjorie Boyer, John J.P. Kastelein · 2015 · Current Opinion in Lipidology
  34. Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?
    Stephen James Nicholls, Adam J. Nelson · 2019 · American Journal of Cardiovascular Drugs
  35. Rare protein-disrupting variants in CETP and protection against vascular events
    Fredrik Landfors, Mathijs de Kleer, John J.P. Kastelein, Elin Chorell · 2024 · medRxiv
  36. HIGH-DENSITY LIPOPROTEINS AND CARDIOVASCULAR DISEASE
    Stephen James Nicholls, Hannah Brown, Kristen J. Bubb · 2020 · EMJ Cardiology
  37. Anacetrapib: potential for the prevention and treatment of coronary heart disease
    Christopher Paul Cannon, Dylan L Steen, Amit V. Khera · 2013 · Research Reports in Clinical Cardiology
  38. HDL – „Game over“?
    Gerald Klose, Rainer Hambrecht · 2013 · Der Kardiologe
  39. Cholesterol efflux as a measure of HDL functionality in humans
    Talbot · 2018
  40. Sodium transport in frog skin: a student laboratory experiment in epithelial physiology.
    Thomas J. Sernka · 1981 · PubMed
  41. Desenvolvimento de um escore de funcionalidade da lipoproteína de alta densidade (HDL) e sua associação com algoritmos de predição de risco cardiovascular e aterosclerose subclínica em indivíduos brasileiros
    Maria Camila Pruper de Freitas · 2019
  42. Lipid-Lowering Drugs
    Kerry‐Anne Rye, Philip J. Barter · 2021 · Springer eBooks
  43. Lipid-Lowering Drugs
    Kerry‐Anne Rye, Philip J. Barter · 2021 · Springer eBooks
  44. Evolving Therapeutic Targets
    Stephen James Nicholls, Adam J. Nelson · 2023 · Elsevier eBooks
  45. Savoir interpréter le HDL cholestérol
    Antonio Gallo, Sarah Chalopin · 2024 · La Presse Médicale Formation
  46. Evolving Targets of Therapy
    Philip J. Barter, Kerry‐Anne Rye · 2015 · Elsevier eBooks
  47. Genetic Architecture of Neurological Disorders and Their Endophenotypes: Insights from Genetic Association Studies
    Muralidharan Sargurupremraj · 2024 · Current topics in behavioral neurosciences
  48. Potential Therapeutic Strategies Targeting CRELD1: Regulation of the Immune Microenvironment in Clear Cell Renal Cell Carcinoma
    Xue Hu, Bosheng Luo, Yingzhuo Li, Yang Wang, Jiaping Wang · 2025 · Research Square
  49. Not Just How Low, But How Stable ― Lipid Variability and Peripheral Artery Disease ―
    Masahiro Katamine, Yoshiyasu Minami · 2025 · Circulation Journal
  50. Monitoring the Progression and Regression of Coronary Atherosclerosis with Intravascular Ultrasound
    Rishi Puri, Stephen James Nicholls · 2014 · Contemporary cardiology
  51. Contribution respective des récepteurs P2Y13 et SR-BI dans le métabolisme du HDL-C et le développement de l'athérosclérose
    Sara Espinosa Delgado · 2017 · theses.fr (ABES)
  52. Identification de nouveaux acteurs du métabolisme des HDL : impact sur les maladies cardiovasculaires
    Lise M. Hardy · 2019 · theses.fr (ABES)
  53. Cross-population proteome-wide mendelian randomization study identifies likely causal proteins for cardiovascular diseases
    Hua Zhong, Jingjing Zhu, Shuai Liu, Hoi Tung Hilton Wong, Yiqiang Zhang, Hung N. Luu, Qing Feng Wu, Xuexia Wang, Lang Wu · 2026 · Molecular Genetics and Genomics
  54. Beyond Traditional Lipid Lowering: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition
    Prashant Thandi, Akshyaya Kumar Pradhan, Rajeev Agarwala, Raman Puri, Marco Alfonso Perrone · 2026 · European Cardiology Review
  55. Efficacy of Combined Obicetrapib and Ezetimibe Versus Obicetrapib Monotherapy in Patients With Existing or At High Risk for ASCVD: A Comprehensive Review and Meta-analysis
    Khushboo Agarwal, Akhila Panduranga Bhandarkar, Shinjan Patra, Deep Dutta, Kunal Mahajan · 2026 · International Journal of Diabetes in Developing Countries
  56. BindingDB Entry 50000438: Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma.
    BindingDB · 2019 · UC San Diego